The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies

Virology

Volumn 409, Issue 2, 2011, Pages 348-359

  Rubio, Ivonne ^a   Seitz, Hanna ^a   Canali, Elena ^b   Sehr, Peter ^c   Bolchi, Angelo ^b   Tommasino, Massimo ^d   Ottonello, Simone ^b   Müller, Martin ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF PARMA   (Italy)

^c EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^d INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Immune epitope; L2 protein; Monoclonal antibody; Neutralization; Prophylactic vaccine; Pseudovirion

Indexed keywords

AMINO ACID; ANTIBODY; CROSS NEUTRALIZING ANTIBODY; EPITOPE; L2 PROTEIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; NON NEUTRALIZING ANTIBODY; PROLINE; THIOREDOXIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANTIBODY ISOLATION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; BINDING SITE; CONTROLLED STUDY; EPITOPE MAPPING; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 31; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREACTIVITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VACCINATION; VIRION; VIRUS NEUTRALIZATION; VIRUS STRAIN; WART VIRUS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BINDING SITES; CAPSID PROTEINS; CROSS REACTIONS; EPITOPE MAPPING; EPITOPES; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PROTEIN BINDING;

BACTERIA (MICROORGANISMS); HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 78650260831     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.10.017     Document Type: Article

References (32)

1. Alphs H.H., Gambhira R., Karanam B., Roberts J.N., Jagu S., Schiller J.T., Zeng W., Jackson D.C., Roden R.B. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc. Natl Acad. Sci. USA 2008, 105(15):5850-5855.
2. Ault K.A. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007, 369(9576):1861-1868.
3. Ault K.A. Human papillomavirus vaccines and the potential for cross-protection between related HPV types. Gynecol. Oncol. 2007, 107(2 Suppl 1):S31-S33.
4. Bossis I., Roden R.B., Gambhira R., Yang R., Tagaya M., Howley P.M., Meneses P.I. Interaction of tSNARE syntaxin 18 with the papillomavirus minor capsid protein mediates infection. J. Virol. 2005, 79(11):6723-6731.
5. Buck C.B., Pastrana D.V., Lowy D.R., Schiller J.T. Generation of HPV pseudovirions using transfection and their use in neutralization assays. Meth. Mol. Med. 2005, 119:445-462.
6. Campos S.K., Ozbun M.A. Two highly conserved cysteine residues in HPV16 L2 form an intramolecular disulfide bond and are critical for infectivity in human keratinocytes. PLoS ONE 2009, 4(2):e4463.
7. Christensen N.D., Reed C.A., Cladel N.M., Hall K., Leiserowitz G.S. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology 1996, 224(2):477-486.
8. Christensen N.D., Cladel N.M., Reed C.A., Budgeon L.R., Embers M.E., Skulsky D.M., McClements W.L., Ludmerer S.W., Jansen K.U. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology 2001, 291(2):324-334.
9. Combita A.L., Touze A., Bousarghin L., Christensen N.D., Coursaget P. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J. Virol. 2002, 76(13):6480-6486.
10. Day P.M., Gambhira R., Roden R.B., Lowy D.R., Schiller J.T. Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J. Virol. 2008, 82(9):4638-4646.
11. Day P.M., Lowy D.R., Schiller J.T. Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids. J. Virol. 2008, 82(24):12565-12568.
12. Gambhira R., Jagu S., Karanam B., Gravitt P.E., Culp T.D., Christensen N.D., Roden R.B. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J. Virol. 2007, 81(21):11585-11592.
13. Gambhira R., Karanam B., Jagu S., Roberts J.N., Buck C.B., Bossis I., Alphs H., Culp T., Christensen N.D., Roden R.B. A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J. Virol. 2007, 81(24):13927-13931.
14. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., Tang G.W., Ferris D.G., Steben M., Bryan J., Taddeo F.J., Railkar R., Esser M.T., Sings H.L., Nelson M., Boslego J., Sattler C., Barr E., Koutsky L.A. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J. Med. 2007, 356(19):1928-1943.
15. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., Jenkins D., Schuind A., Costa Clemens S.A., Dubin G. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367(9518):1247-1255.
16. Jagu S., Karanam B., Gambhira R., Chivukula S.V., Chaganti R.J., Lowy D.R., Schiller J.T., Roden R.B. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J. Natl Cancer Inst. 2009, 101(11):782-792.
17. Kawana K., Yoshikawa H., Taketani Y., Yoshiike K., Kanda T. Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. J. Virol. 1999, 73(7):6188-6190.
18. Kawana K., Kawana Y., Yoshikawa H., Taketani Y., Yoshiike K., Kanda T. Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies. Vaccine 2001, 19(11-12):1496-1502.
19. Kawana K., Yasugi T., Kanda T., Kino N., Oda K., Okada S., Kawana Y., Nei T., Takada T., Toyoshima S., Tsuchiya A., Kondo K., Yoshikawa H., Tsutsumi O., Taketani Y. Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers. Vaccine 2003, 21(27-30):4256-4260.
20. Kondo K., Ishii Y., Ochi H., Matsumoto T., Yoshikawa H., Kanda T. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virology 2007, 358(2):266-272.
21. Kondo K., Ochi H., Matsumoto T., Yoshikawa H., Kanda T. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. J. Med. Virol. 2008, 80(5):841-846.
22. Laniosz V., Nguyen K.C., Meneses P.I. Bovine papillomavirus type 1 infection is mediated by SNARE syntaxin 18. J. Virol. 2007, 81(14):7435-7448.
23. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., Snijders P.J., Meijer C.J. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J. Med. 2003, 348(6):518-527.
24. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D.L., Kitchener H.C., Castellsague X., de Carvalho N.S., Skinner S.R., Harper D.M., Hedrick J.A., Jaisamrarn U., Limson G.A., Dionne M., Quint W., Spiessens B., Peeters P., Struyf F., Wieting S.L., Lehtinen M.O., Dubin G. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369(9580):2161-2170.
25. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., Kitchener H., Castellsague X., Teixeira J.C., Skinner S.R., Hedrick J., Jaisamrarn U., Limson G., Garland S., Szarewski A., Romanowski B., Aoki F.Y., Schwarz T.F., Poppe W.A., Bosch F.X., Jenkins D., Hardt K., Zahaf T., Descamps D., Struyf F., Lehtinen M., Dubin G., Greenacre M. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374(9686):301-314.
26. Pastrana D.V., Gambhira R., Buck C.B., Pang Y.Y., Thompson C.D., Culp T.D., Christensen N.D., Lowy D.R., Schiller J.T., Roden R.B. Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 2005, 337(2):365-372.
27. Richards R.M., Lowy D.R., Schiller J.T., Day P.M. Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc. Natl Acad. Sci. USA 2006, 103(5):1522-1527.
28. Rizk R.Z., Christensen N.D., Michael K.M., Muller M., Sehr P., Waterboer T., Pawlita M. Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J. Gen. Virol. 2008, 89(Pt 1):117-129.
29. Rubio I., Bolchi A., Moretto N., Canali E., Gissmann L., Tommasino M., Muller M., Ottonello S. Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20-38) peptide displayed on bacterial thioredoxin. Vaccine 2009, 27(13):1949-1956.
30. Schellenbacher C., Roden R., Kirnbauer R. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J. Virol. 2009.
31. Sehr P., Zumbach K., Pawlita M. A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. J. Immunol. Meth. 2001, 253(1-2):153-162.
32. Slupetzky K., Gambhira R., Culp T.D., Shafti-Keramat S., Schellenbacher C., Christensen N.D., Roden R.B., Kirnbauer R. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine 2007, 25(11):2001-2010.